Inflammation and Pain Post Cataract Surgery Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Formosa Pharmaceuticals, Inc., Xigen, Eyepoint Pharmaceuticals, Alcon Research, Oculis Pharma

The Inflammation and Pain Post Cataract Surgery Market is set to register immense growth in the coming years owing to the rise in the number of prevalent population of Inflammation and Pain Post Cataract Surgery patients in the 7MM, the improvement in the diagnosis methodologies, raising awareness of the complication, incremental healthcare spending across the world, and the expected launch of emerging therapies.

DelveInsight's "Inflammation and Pain Post Cataract Surgery Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Inflammation and Pain Post Cataract Surgery Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Inflammation and Pain Post Cataract Surgery therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Inflammation and Pain Post Cataract Surgery treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Inflammation and Pain Post Cataract Surgery: An Overview
Cataract surgery, also called lens replacement surgery, is the removal of the natural lens of the eye that has developed an opacification, which is referred to as a cataract, and its replacement with an intraocular lens. Cataract is the leading cause of blindness in the world, accounting for half of blindness and affecting about 20 million people. Although cataract surgery is an effective method for restoring vision, individuals in developing countries have limited access to cataract surgery services. In addition, cataracts is also one of the major socioeconomic and public health burdens, even in developed countries. This is because the volume of cataract surgery has increased due to an aging population and an increase in cataract surgery services.

Post-cataract surgery inflammation presents as protein flare and inflammatory cells in the anterior chamber, hyperaemia, miosis, oedema, leukocyte migration, fibroblast proliferation, and scar formation, along with other local responses to the released pro-inflammatory cytokines.

Acute postoperative endophthalmitis occurs within 6 weeks after cataract surgery and should always be considered in the differential diagnosis of postoperative inflammation. Acute postoperative endophthalmitis is usually diagnosed by vitreous culture, although up to 30% of cases may be culture-negative. Evidence-based management of postoperative endophthalmitis is largely guided by the EVS, which demonstrated equivalent outcomes for intravitreal antibiotics or pars plana vitrectomy with antibiotics for patients with hand motions or better-presenting vision.

The causes of chronic postoperative inflammation are broadly similar to those for acute disease, including infection and lens-related inflammation. Additionally, mechanical iritis may result in chronic inflammation following surgery.

Pain after ophthalmic surgery is often considered a sign of a possible complication. Severe pain is assumed to be a sign of postoperative inflammation or infection, making it a concern for both patient and physician. However, surgery without perioperative complications may also be associated with significant postoperative pain during the early recovery. Thus, appropriate

Inflammation and Pain Post Cataract Surgery Market Key Facts
• As per Tiihonen et al. 2013, although cataract extraction is common, little is known about postoperative recovery and pain after phacoemulsification with IOL implantation.
• According to another paper by Taravati et al., 2012 postoperative inflammation following cataract surgery is a typical occurrence, but is usually easily managed and of limited clinical impact. It is usually divided into acute and chronic phases, depending upon the duration of the impact.
• According to Hannu Kokki et al., in the article "Postoperative pain after cataract surgery", the reported incidence of early-onset ocular pain varied significantly between 6% and 95%, and the incidence of moderate or severe pain was 1% to 35% across the studies. The incidence of moderate or severe pain was 71% to 85% at 2 hours after surgery, and 30% to 36% of the patients still reported significant pain at 6 hours.
• Postoperative pain is relatively common during the first hours after surgery, and studies show that around ~34% of the cases experience such symptoms.

Get a Detailed Overview of the Evolving Inflammation and Pain Post Cataract Surgery Market Trends @
https://www.delveinsight.com/report-store/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Inflammation and Pain Post Cataract Surgery Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Inflammation and Pain Post Cataract Surgery therapies in the market. It also provides a detailed assessment of the Inflammation and Pain Post Cataract Surgery market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Inflammation and Pain Post Cataract Surgery drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Inflammation and Pain Post Cataract Surgery Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Inflammation and Pain Post Cataract Surgery Epidemiology
The epidemiology section covers detailed insights into the historical, and current Inflammation and Pain Post Cataract Surgery patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Inflammation and Pain Post Cataract Surgery Epidemiology Segmented as -
• Total Incident cases of cataracts in the 7MM (2019-2032)
• Total Incident Cases undergoing Cataract surgery in 7MM (2019-2032)
• Total Incident Cases of Inflammation and Pain Post Cataract Surgery in the 7MM (2019-2032)
• Treatable Cases of Inflammation and Pain Post Cataract Surgery in the 7MM (2019-2032)

Get Key Insights Into the Evolving Inflammation and Pain Post Cataract Surgery Epidemiology Trends @
https://www.delveinsight.com/report-store/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Inflammation and Pain Post Cataract Surgery Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammation and Pain Post Cataract Surgery market or expected to be launched during the study period. The analysis covers the market share by Inflammation and Pain Post Cataract Surgery drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Inflammation and Pain Post Cataract Surgery Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Inflammation and Pain Post Cataract Surgery Market @
https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Inflammation and Pain Post Cataract Surgery Therapeutics Assessment
There are no established treatment guidelines to prevent or reduce inflammation following cataract surgery. Therefore, treatment includes pre- and post-operative anti-inflammatory therapies such as corticosteroids and NSAIDs. Since it is impossible to predict which patients will develop clinically significant post-operative inflammation, anti-inflammatory agents are routinely used postoperatively.

The rising number of patients with Inflammation and Pain Post Cataract Surgery, increasing awareness, and increasing research and development activities are some of the factors that are expected to contribute towards the market growth. With the increasing demand and awareness, pharmaceutical companies are working to develop several novel Inflammation and Pain Post Cataract Surgery drugs and launch their novel product in the upcoming years.

A few major pharma and biotech companies are developing therapies for Inflammation and Pain Post Cataract Surgery. Currently, Formosa Pharmaceuticals is leading the therapeutics market with its Inflammation and Pain Post Cataract Surgery drug candidates in the most advanced stage of clinical development.

Leading Companies in the Inflammation and Pain Post Cataract Surgery Therapeutics Market Include
• Formosa Pharmaceuticals, Inc.
• Xigen
• EYEPOINT PHARMACEUTICALS
• Alcon Research
• Oculis Pharma
And Many Others

Emerging and Marketed Inflammation and Pain Post Cataract Surgery Therapies Covered in the Report Include
• APP13007 : Formosa Pharmaceuticals
• DEXYCU: EYEPOINT PHARMACEUTICALS
• Nepafenac: Alcon Research
• OCS-01 : Oculis Pharma
And many more

Learn More About the Emerging Therapies and key Companies in the Inflammation and Pain Post Cataract Surgery Therapeutics Market @
https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Inflammation and Pain Post Cataract Surgery Competitive Intelligence Analysis
4. Inflammation and Pain Post Cataract Surgery Market Overview at a Glance
5. Inflammation and Pain Post Cataract Surgery Background and Overview
6. Inflammation and Pain Post Cataract Surgery Patient Journey
7. Inflammation and Pain Post Cataract Surgery Epidemiology and Patient Population
8. Inflammation and Pain Post Cataract Surgery Treatment Algorithm, Current Treatment, and Medical Practices
9. Inflammation and Pain Post Cataract Surgery Unmet Needs
10. Key Endpoints of Inflammation and Pain Post Cataract Surgery Treatment
11. Inflammation and Pain Post Cataract Surgery Marketed Products
12. Inflammation and Pain Post Cataract Surgery Emerging Therapies
13. Inflammation and Pain Post Cataract Surgery Seven Major Market Analysis
14. Attribute Analysis
15. Inflammation and Pain Post Cataract Surgery Market Outlook (7 major markets)
16. Inflammation and Pain Post Cataract Surgery Access and Reimbursement Overview
17. KOL Views on the Inflammation and Pain Post Cataract Surgery Market.
18. Inflammation and Pain Post Cataract Surgery Market Drivers
19. Inflammation and Pain Post Cataract Surgery Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.